Which combined oral contraceptive preparation has regulatory approval specifically for the treatment of premenstrual dysphoric disorder?
- A Levonorgestrel 150 mcg with ethinyl estradiol 30 mcg
- B Drospirenone 3 mg with ethinyl estradiol 20 mcg ✓
- C Norethisterone 1 mg with ethinyl estradiol 35 mcg
- D Desogestrel 150 mcg with ethinyl estradiol 30 mcg
Correct answer: B. Drospirenone 3 mg with ethinyl estradiol 20 mcg
Explanation
The 24/4 regimen containing drospirenone 3 mg with ethinyl estradiol 20 mcg is approved for PMDD; drospirenone is a progestin with anti-mineralocorticoid and antiandrogenic activity, which counters the luteal bloating and mood symptoms. Older levonorgestrel, norethisterone, and desogestrel combinations lack approval for PMDD, and androgenic progestins can actually worsen premenstrual mood symptoms.
Reference: Katzung's Basic and Clinical Pharmacology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.